[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency].
Kidney independent glycosides offer a high measure of therapeutic safety in comparison with kidney dependent glycosides. The intoxication rate lies between 4 and 6%. The pharmacokinetic properties of pentaformylgitoxin (INN: gitoformate) are comparable with those for digitoxin. The active glycoside 16-formylgitoxin (INN: gitaloxin) is formed by rapid deformylation of the formyl residue on the sugar chain. The maintenance dose of 0.06 mg daily, based on the half-life, produces therapeutic concentrations in the range 6-30 ng/ml. The required loading dose, as for digitoxin, amounts to 10 times the maintenance dose.
D002301:Cardiac Glycosides / Q000378:metabolism; D004074:Digitoxin / Q000009:adverse effects / Q000627:therapeutic use*; D004077:Digoxin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007008:Hypokalemia / Q000209:etiology; D007668:Kidney / Q000187:drug effects*; D011485:Protein Binding; D012306:Risk; D012709:Serum Albumin / Q000378:metabolism
D002301:Cardiac Glycosides; D012709:Serum Albumin; D004077:Digoxin; C008785:pentaformylgitoxin; D004074:Digitoxin
Gitoformat und Digitoxin als Alternative zu nierenpflichtigen Glykosiden in der Therapie der Herzinsuffizienz.